Research Article

Receptor-mediated induction of human dermal fibroblast ectoaminopeptidase N by glucocorticoids

V. Stefanović*, P. Vlahović and M. Mitic´-Zlatkovic´

Institute of Nephrology and Hemodialysis, Faculty of Medicine, B. Taskovića 48, YU-18000 Niš (Yugoslavia), Fax +381 18 321 313

Received 3 April 1998; accepted 21 April 1998

Abstract. Aminopeptidase N was demonstrated in human dermal fibroblasts as an ectoenzyme. The enzyme has wide substrate specificity, with a $K_m$ of 0.63 mM and $V_{max}$ of 338 nmol min$^{-1}$ mg$^{-1}$. Addition of fetal calf serum to the culture medium increased aminopeptidase N activity up to 63% by 10% serum in a 48-h culture. Treatment of fibroblasts by dexamethasone increased ectoaminopeptidase N activity in a dose- and time-dependent manner. Maximal increase of aminopeptidase N activity occurred after treatment with 1 μM dexamethasone for 3 days. Actinomycin D, a blocker of RNA synthesis, and cycloheximide, an inhibitor of protein synthesis, did not alter basal aminopeptidase N activity. However, they prevented stimulation by dexamethasone. RU 38486, a glucocorticoid receptor antagonist, suppressed the dexamethasone-induced increase in aminopeptidase N activity. This study shows that human dermal fibroblasts contain ectoaminopeptidase N controlled by glucocorticoids through a receptor-mediated mechanism.

Key words. Dermal fibroblasts; aminopeptidase N; ectoenzyme; glucocorticoids.

Ectopeptidases play an important role in signal transduction and communication between cells [1]. Aminopeptidases have attracted much interest, and several different types of these enzymes, N, A, B, P and W, have been described. Aminopeptidase N (APN; L-$\alpha$-aminoacylpeptide hydrolase, EC 3.4.11.2) acts with relatively broad substrate specificity on peptides with an N-terminal neutral amino acid. Aminopeptidase N is widely distributed, with the highest expression in renal cortex and intestinal microvilli [2]. Sequence analysis showed aminopeptidase N to be identical to CD 13, a 150-kDa cell surface glycoprotein originally used as a marker for subpopulations of haematopoietic cells [3].

Its presence on the surface of myeloid cells is thought to be immunoregulatory in nature [4]. Aminopeptidase N is thought to participate in the degradation of regulatory peptides such as enkephalins [5]. Human dermal fibroblasts function to synthesize and degrade the extracellular matrix, as well as to secrete diffusible factors that promote epidermal cell growth [6]. Several membrane-bound proteases have been demonstrated on human skin fibroblasts, and their modulation in pathology has been suggested [7]. The aim of this work was to study regulation of human dermal fibroblast aminopeptidase N by cyclic adenosine monophosphate (cAMP), growth factors and glucocorticoids. Evidence is presented that fibroblast aminopeptidase N is upregulated by glucocorticoids through a receptor-mediated mechanism.

* Corresponding author.
Materials and methods

Tissue culture flasks, dishes and culture media were obtained from Flow Laboratories (Irvine, UK); actinomycin D, alanine p-nitroanilide (p-NA), 8-bromo-cAMP, cycloheximide, dexamethasone and phorbol-12-miristate-13-acetate (PMA) from Sigma (St. Louis, MO, USA). The glucocorticoid antagonist, RU 38486, was a gift from Roussel-Uclaf (Paris, France).

Culture of dermal fibroblasts. Human fibroblasts were isolated from fragments of skin taken during surgery in the trunk area of normal adult subjects. The explant culture was performed as described previously [7]. Cells were cultured in RPMI 1640 medium buffered with 20 mM Hepes and supplemented with 10% fetal calf serum, 50 U/ml of penicillin, 50 mg/ml of streptomycin sulphate and 2 mM L-glutamine. Fibroblasts were used for experiments between the 6th and 10th passage.

Aminopeptidase N activity. Surface aminopeptidase N activity was determined on cultures of human dermal fibroblasts in 24-well plates. Cells were rinsed three times and incubated at 37 °C in phosphate-buffered saline (pH 7.8) containing NaCl (140 mM), MgCl₂ (1.0 mM), Na₂HPO₄ (9 mM), NaH₂PO₄ (9 mM), KH₂PO₄ (1.5 mM) and KCl (3 mM). Alanine p-NA (3.0 mM) was used as substrate. The amount of p-NA formed was read at an optical density of 405 nm. Cell-free and substrate-free blanks were run in parallel. Cell protein was estimated by the method of Lowry et al. [8], after appropriate digestion with 1 M NaOH. Enzyme activity was expressed as nanomoles of p-NA formed per minute and per milligram of cell protein.

Results

Characterization of fibroblast aminopeptidase N. Aminopeptidase N in these cells was considered as an ectoenzyme on the following grounds: (i) the substrate was hydrolysed by intact cells in culture, and the product was released in the extracellular medium; (ii) the amount of substrate hydrolysed over 3 to 15 min was linearly related to the length of incubation, so it is unlikely that significant hydrolysis of the substrate occurred after entry into the cell; (iii) aminopeptidase N activity of cells treated with the diazonium salt of sulphanilic acid (DASA) (0.01–3.5 mM), a nonpenetrating agent that forms covalent bonds with many proteins and lipids at the cell membrane, as described previously [9], rapidly decreased to about 25% of the basal level at 3.5 mM DASA; (iv) aminopeptidase N activity in the medium after 15 to 30 min incubation of cells was negligible, demonstrating that the enzyme was not released from the cells.

Substrate specificity of the enzyme was broad, as demonstrated by hydrolysis of several chromogenic substrates (table 1). Alanine p-NA was hydrolysed at a higher rate than leucine p-NA, with a \( K_m \) of 0.63 mM and \( V_{max} \) of 338 nmol min \(^{-1} \) mg \(^{-1} \).

Culture medium supplemented with 1 to 30% fetal calf serum for 24 to 48 h increased aminopeptidase N activity (fig. 1). Maximal increase was obtained in a 48-h culture with 10% fetal calf serum (\( P < 0.01 \)). In order to determine the characteristics of stimulatory factors, fetal calf serum was subjected to heating and dialysis. Stimulatory activity was maintained after 24 h of dialysis at 4 °C. In contrast, aminopeptidase N induction was nearly completely suppressed by heating serum at 100 °C for 5 min (data not shown). cAMP treatment of cell culture in concentrations from 10 to 500 \( \mu \)M for 72 h revealed no effect on aminopeptidase N activity (data not shown). PMA treatment of cultured dermal fibroblasts, in concentrations of 0.1 to 10 ng/ml for 24 and 48 h did not change surface aminopeptidase N activity (data not shown).

Table 1. Hydrolysis of various chromogenic substrates by human fibroblast aminopeptidases.

| Substrate | Aminopeptidase activity (nmol min \(^{-1} \) mg \(^{-1} \)) |
|-----------|-------------------------------------------------|
| Alanine p-NA | 110 ± 8.6 |
| Leucine p-NA | 92.3 ± 3.8 |
| Lysine p-NA | 48.2 ± 6.6 |
| Arginine p-NA | 47.1 ± 5.6 |
| Valine p-NA | 6.2 ± 1.5 |
| Proline p-NA | 1.4 ± 0.4 |

Figure 1. Effect of serum factors on dermal fibroblast aminopeptidase N. Fibroblasts were cultured for 24 and 48 h with 0–30% fetal calf serum. Enzyme activity is given as percent of basal value. Means ± SD of four determinations are given. Regression analysis showed a significant effect of serum on aminopeptidase N activity in both 24-h (\( P < 0.01 \)) and 48-h (\( P < 0.001 \)) cultures. *\( P < 0.01 \) vs. control.
Dexamethasone induction of fibroblast aminopeptidase N

Figure 2. Effect of dexamethasone treatment on dermal fibroblast aminopeptidase N. Fibroblasts were cultured with dexamethasone in the concentration range from 0.01 to 100 μM in a medium supplemented with 10% fetal calf serum for 1, 3 and 5 days. Enzyme activity is given as percent of basal value. Means ± SD of four determinations are given. Regression analysis showed that aminopeptidase N activity significantly correlated with the concentration of dexamethasone (P < 0.001) at all lengths – 1, 3 and 5 – days of treatment.

Human dermal fibroblasts were treated with dexamethasone in a concentration range from 0.01 to 100 μM for up to 5 days. Aminopeptidase N activity of fibroblasts treated with dexamethasone increased significantly (fig. 2). The effect was significant (P < 0.05) at 1.0 μM dexamethasone after 1 day of treatment, but at lower concentrations after 3 and 5 days of treatment. The enzyme activity doubled after 3 days of treatment with 0.1 and 1.0 μM dexamethasone. To evaluate whether the effect of dexamethasone on aminopeptidase N activity required synthesis of a new enzyme, fibroblasts were treated with actinomycin D, an inhibitor of RNA synthesis, and cycloheximide, an inhibitor of protein synthesis. Stimulation of aminopeptidase N was blocked by both inhibitors (table 2). Receptor occupancy by RU 38486, a glucocorticoid receptor antagonist, also prevented induction of aminopeptidase N by dexamethasone.

Discussion

In this study we present evidence that human fibroblast aminopeptidase N is an ectoenzyme. Wide substrate specificity was found, with a K_m for L-alanine p-NA in the millimolar range, as described in a previous study [7]. Growth factors, present in the serum, increased aminopeptidase N activity of dermal fibroblasts, in contrast with an increase in human mesangial cell aminopeptidase N upon serum withdrawal [10]. The fact that serum stimulatory factor was not dialysable and that its activity was suppressed by heating the serum at 100 °C for 5 min before addition to the culture suggest that this factor is probably a protein or peptide. Fetal calf serum contains some growth factors which could influence aminopeptidase N expression. Previously, we identified in serum epidermal growth factor (EGF) and showed that aminopeptidase N is upregulated upon treatment of human mesangial cells with nanomolar concentrations of EGF [11]. Dermal fibroblast aminopeptidase N was unaffected following treatment with cAMP in the concentration range from 10 to 500 μM. This is different from mesangial cell aminopeptidase N, which was stimulated with cAMP and cAMP-stimulating agents [10]. PMA treatment had no effect on dermal fibroblast aminopeptidase N; however, it caused marked induction of the enzyme in glomerular mesangial and epithelial cells [9, 12]. Dexamethasone treatment induced dermal fibroblast aminopeptidase N but had no effect on the enzyme in glomerular mesangial cells [10]. Taken together, these data show varied regulation of aminopeptidase N in human dermal

Table 2. Effects of cycloheximide, actinomycin D and RU 38486 on dexamethasone-induced aminopeptidase N activity in human fibroblasts.

| Treatment                      | Aminopeptidase N activity (nmol min^{-1} mg^{-1}) |
|-------------------------------|---------------------------------------------------|
| Control                       | 108 ± 12.4                                        |
| Dexamethasone, 1 μM            | 180 ± 14.3                                        |
| Cycloheximide, 0.1 μg/ml       | 91 ± 8.6                                          |
| Dexamethasone, 1 μM + cycloheximide, 0.1 μg/ml | 101 ± 11.7                                      |
| Actinomycin D, 0.1 μg/ml       | 96 ± 9.4                                          |
| Dexamethasone, 1 μM + actinomycin D, 0.1 μg/ml | 106 ± 6.5                                       |
| RU 38486, 10 μM                | 95 ± 9.7                                          |
| Dexamethasone, 1 μM + RU 38486, 10 μM | 99 ± 15.5                                      |

Cells were preincubated with cycloheximide, actinomycin D or RU 38486 for 1 h before addition of dexamethasone and were then incubated for a further period of 72 h. Values are means ± SD of four determinations. Data were analysed using two-way analysis of variance. The effect of dexamethasone was statistically significant (P < 0.001). Interactions between dexamethasone and each of the agents tested (cycloheximide, actinomycin D, RU 38486) were also significant (P < 0.001).
fibroblasts and glomerular mesangial cells by cAMP, growth factors, mitogens and glucocorticoids.

Dexamethasone treatment was found to induce dermal fibroblast aminopeptidase N. This effect was time- and dose-dependent. The increase in aminopeptidase N was inhibited by actinomycin D and cycloheximide, suggesting that enzyme protein synthesis is responsible for the increased activity. RU 38486, a glucocorticoid receptor antagonist, prevented the increase in aminopeptidase N expression and functional activity of human dermal fibroblasts. IL-1 had increased both expression and functional activity of human dermal fibroblast aminopeptidase N [14]. IL-1 had no effect on fibroblast aminopeptidase N [14]. IL-1 had no effect on fibroblast aminopeptidase N (Stefanovic et al., unpublished observations). Other cytokines tested (tumour necrosis factor α and platelet-derived growth factor) were found to have no effect on expression of aminopeptidase N in fibroblasts [14].

The physiological role of surface aminopeptidase N in human dermal fibroblasts has not been established. Due to its broad substrate specificity aminopeptidase N cleaves various peptides, leading to activation or inactivation of certain biologically active peptides. Aminopeptidase N is thought to participate in the degradation of neuropeptides, such as enkephalins, endorphins and opioid peptides [5]. Apart from their degradative role, the second major property of cell surface proteases is their role as signal-transducing molecules. They transfer information into cells by acting as coreceptors along with more traditional receptors. In glomerular mesangial cells aminopeptidase N is a receptor for angiotensin IV [15]. Recent evidence suggests that epithelial cell CD 13 serves as a receptor for human coronavirus [16]. The presence of aminopeptidase N on the surface of myeloid cells is thought to be immunoregulatory in nature [4]. In the dermis fibroblasts synthesize and degrade the extracellular matrix, and promote epidermal cell growth [6]. The exact role of fibroblast ectopeptidases in these processes is not yet understood. However, dermal fibroblast Arg- and Leu-aminopeptidase and dipeptidylpeptidase IV activities were found to be increased in rheumatoid arthritis, psoriasis and lichen planus. A potential role for these peptidases in the modulation of matrix catabolism has been suggested [7].

This study demonstrates that glucocorticoids control the expression of fibroblast aminopeptidase N. The effect was specific for glucocorticoids and was obtained with concentrations (0.1 μM) of dexamethasone corresponding to physiologic corticoid concentrations. Thus aminopeptidase N expression in human dermal fibroblasts may be influenced by both normal corticoid secretion and pharmacological drug administration.

1 Kenny A. J., Stephenson S. L. and Turner A. J. (1987) Cell surface proteases. In: Mammalian Ectoenzymes, Kenny A. J. and Turner A. J. (eds), pp. 169–210, Elsevier, Amsterdam
2 Kenny A. J. and Maroux S. (1982) Topology of microvillus membrane hydrolases of kidney and intestine. Physiol. Rev. 62: 91–128
3 Look A. T., Ashmun R. A., Shapiro L. H. and Peiper S. C. (1989) Human myeloid plasma membrane glycoprotein CD 13 (gr 150) is identical to aminopeptidase N. J. Clin. Invest. 83: 1299–1307
4 Saito M., Aoyagi T., Umezawa H. and Nagai Y. (1977) Bestatin, a new specific inhibitor of aminopeptidases, enhances activation of small lymphocytes by concanavalin A. Biochem. Biophys. Res. Commun. 76: 526–533
5 Turner A. J., Matsas R. and Kenny A. J. (1985) Are there neuropeptide-specific peptidases? Biochem. Pharmacol. 34: 1347–1356
6 Finch P. W., Rubin J. S., Miki T. and Aaronson S. A. (1989) Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science 245: 752–755
7 Raynaud F., Bauvois B., Gerbaud P. and Evain-Brion D. (1992) Characterization of specific proteases associated with the surface of human skin fibroblasts, and their modulation in pathology. J. Cell. Physiol. 151: 378–385
8 Lowry O. H., Rosebrough N. J., Farr A. L. and Randall R. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265
9 Stefanovic V., Vlahovic P., Ardaillou N., Ronco P., Nivez M. P. and Ardaillou R. (1992) Characterization and control of expression of cell surface aminopeptidase N activity in human mesangial glomerular cells. Cell. Physiol. Biochem. 2: 57
10 Stefanovic V. and Vlahovic P. (1995) Regulation of expression of surface aminopeptidase N in human glomerular mesangial cells. Cell. Physiol. Biochem. 5: 127
11 Stefanovic V., Vlahovic P. and Mitić-Zlatković M. (1998) Epidermal growth factor upregulates aminopeptidase N and 5' nucleotidase in human glomerular mesangial cells. Kidney Blood Press. Regul., in press
12 Stefanovic V., Vlahovic P., Ardaillou N., Ronco P. and Ardaillou R. (1992) Cell surface aminopeptidase A and N activities in human mesangial epithelial cells. Kidney Int. 41: 1571–1580
13 Phelps D. S. and Litwack G. (1982) An electroforetic characterization of the glucocorticoid response of the Fu 5-5 rat hepatoma cell line. Eur. J. Biochem. 126: 407–415
14 Piela-Smith T. H. and Korn J. H. (1995) Aminopeptidase N: a constitutive cell-surface protein on human dermal fibroblasts. Cell. Immunol. 162: 42–48
15 Chansel D., Ruffet E., Vandermeersch S., Fournie-Zaluski M. C. and Ardaillou R. (1997) Aminopeptidases are the major binding site for angiotensin IV on rat mesangial cells. J. Am. Soc. Nephrol. 8: 400A
16 Yeager C. L., Ashmun R. A., Williams R. K., Cardellichio C. B., Shapiro L. H., Look A. T. et al. (1992) Human aminopeptidase N is a receptor for human coronavirus 229E. Nature 357: 420–422